Imunon annual debt-to-assets ratio
2012
2013
2017
2018
2019
2020
2021
2022
2023
2024
2025
Imunon Debt-to-Assets Ratio Growth & History (IMNN)
Imunon's debt-to-assets ratio was 0.08 for fiscal 2025.
View full Imunon company overviewImunon annual debt-to-assets ratio history
| Fiscal year | Period ended | Debt-to-assets ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 0.08 | −0.04 | −29.98% |
| 2024 | 2024-12-31 | 0.12 | 0.04 | +58.17% |
| 2023 | 2023-12-31 | 0.07 | −0.07 | −47.38% |
| 2022 | 2022-12-31 | 0.14 | 0.13 | +1237.99% |
| 2021 | 2021-12-31 | 0.01 | −0.15 | −93.62% |
| 2020 | 2020-12-31 | 0.17 | −0.13 | −44.25% |
| 2019 | 2019-12-31 | 0.30 | 0.07 | +29.47% |
| 2018 | 2018-12-31 | 0.23 | 0.23 | +15077.97% |
| 2017 | 2017-12-31 | 0.00 | — | — |
| 2013 | 2013-12-31 | 0.11 | −0.09 | −44.35% |
| 2012 | 2012-12-31 | 0.20 | — | — |
Imunon quarterly debt-to-assets ratio
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q4.13
Q1.14
Q2.14
Q4.17
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
| Fiscal quarter | Period ended | Debt-to-assets ratio | Change | YoY change |
|---|---|---|---|---|
| Q1 2026 | 2026-03-31 | 0.11 | −0.03 | −22.60% |
| Q4 2025 | 2025-12-31 | 0.08 | −0.04 | −29.98% |
| Q3 2025 | 2025-09-30 | 0.12 | 0.03 | +39.39% |
| Q2 2025 | 2025-06-30 | 0.14 | −0.01 | −5.26% |
| Q1 2025 | 2025-03-31 | 0.15 | 0.04 | +39.48% |
| Q4 2024 | 2024-12-31 | 0.12 | 0.04 | +58.17% |
| Q3 2024 | 2024-09-30 | 0.09 | 0.02 | +24.90% |
| Q2 2024 | 2024-06-30 | 0.14 | 0.10 | +202.50% |
| Q1 2024 | 2024-03-31 | 0.11 | −0.07 | −41.43% |
| Q4 2023 | 2023-12-31 | 0.07 | −0.07 | −47.38% |
| Q3 2023 | 2023-09-30 | 0.07 | −0.03 | −32.99% |
| Q2 2023 | 2023-06-30 | 0.05 | −0.05 | −52.07% |
| Q1 2023 | 2023-03-31 | 0.18 | 0.08 | +76.70% |
| Q4 2022 | 2022-12-31 | 0.14 | 0.13 | +1237.99% |
| Q3 2022 | 2022-09-30 | 0.11 | 0.02 | +23.55% |
| Q2 2022 | 2022-06-30 | 0.10 | 0.02 | +22.55% |
| Q1 2022 | 2022-03-31 | 0.10 | 0.02 | +21.29% |
| Q4 2021 | 2021-12-31 | 0.01 | −0.15 | −93.62% |
| Q3 2021 | 2021-09-30 | 0.09 | −0.08 | −49.56% |
| Q2 2021 | 2021-06-30 | 0.08 | −0.16 | −66.76% |
| Q1 2021 | 2021-03-31 | 0.08 | −0.21 | −71.19% |
| Q4 2020 | 2020-12-31 | 0.17 | −0.13 | −44.25% |
| Q3 2020 | 2020-09-30 | 0.17 | −0.11 | −39.59% |
| Q2 2020 | 2020-06-30 | 0.24 | −0.02 | −6.54% |
| Q1 2020 | 2020-03-31 | 0.29 | 0.04 | +17.01% |
| Q4 2019 | 2019-12-31 | 0.30 | 0.07 | +29.47% |
| Q3 2019 | 2019-09-30 | 0.28 | 0.05 | +22.59% |
| Q2 2019 | 2019-06-30 | 0.26 | 0.07 | +39.41% |
| Q1 2019 | 2019-03-31 | 0.25 | — | — |
| Q4 2018 | 2018-12-31 | 0.23 | 0.23 | +15077.97% |
| Q3 2018 | 2018-09-30 | 0.23 | — | — |
| Q2 2018 | 2018-06-30 | 0.19 | — | — |
| Q4 2017 | 2017-12-31 | 0.00 | — | — |
| Q2 2014 | 2014-06-30 | 0.13 | 0.03 | +36.10% |
| Q1 2014 | 2014-03-31 | 0.09 | −0.01 | −12.34% |
| Q4 2013 | 2013-12-31 | 0.11 | −0.09 | −44.35% |
| Q2 2013 | 2013-06-30 | 0.09 | −0.10 | −51.95% |
| Q1 2013 | 2013-03-31 | 0.10 | — | — |
| Q4 2012 | 2012-12-31 | 0.20 | — | — |
| Q3 2012 | 2012-09-30 | 0.20 | — | — |
| Q2 2012 | 2012-06-30 | 0.19 | — | — |
Imunon debt-to-assets ratio trends
Over the last five fiscal years, Imunon's debt-to-assets ratio decreased from 0.17 to 0.08, a change of −0.08. The latest reported quarter, Q1 2026, shows 0.11.
About the metric
What the debt-to-assets ratio means
The debt-to-assets ratio shows the portion of a company’s reported assets financed with interest-bearing debt. It is a leverage measure and should not be confused with total liabilities divided by assets.
Calculation and source
How debt-to-assets is calculated
TickerStat calculates debt-to-assets as total interest-bearing debt divided by total assets at the same reporting-period end. Periods with missing debt or non-positive assets are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Imunon source filings ↗Community posts
IMUNON signs an NCI agreement to expand development of IMNN-001
IMUNON ($IMNN) entered a Cooperative Research and Development Agreement with the US National Cancer Institute for IMNN-001, its DNA-based IL-12 immunotherapy. NCI’s Cancer Therapy Evaluation Program will assume regulatory sponsorship and su ...